Top-Rated StocksTop-RatedNASDAQ:CMPX Compass Therapeutics (CMPX) Stock Price, News & Analysis $2.95 -0.02 (-0.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.95 0.00 (0.00%) As of 08/1/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Compass Therapeutics Stock (NASDAQ:CMPX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Compass Therapeutics alerts:Sign Up Key Stats Today's Range$2.80▼$2.9750-Day Range$2.09▼$3.3352-Week Range$0.87▼$4.08Volume815,258 shsAverage Volume713,431 shsMarket Capitalization$407.93 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingBuy Company Overview Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Read More Compass Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCMPX MarketRank™: Compass Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 557th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCompass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompass Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Compass Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.36) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -7.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -7.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Compass Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.91% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Compass Therapeutics has recently increased by 6.09%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.91% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Compass Therapeutics has recently increased by 6.09%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News SentimentN/A Search Interest5 people have searched for CMPX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows11 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,100.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders29.80% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Therapeutics' insider trading history. Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPX Stock News HeadlinesCMPX Compass Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comCompass Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.August 2 at 2:00 AM | Weiss Ratings (Ad)Stifel Nicolaus Sticks to Its Buy Rating for Compass Therapeutics (CMPX)May 11, 2025 | theglobeandmail.comCompass Therapeutics price target lowered to $10 from $12 at GuggenheimMay 9, 2025 | msn.comCompass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.comCompass Therapeutics to Participate in Upcoming May Investor EventsMay 6, 2025 | globenewswire.comCompass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual MeetingApril 28, 2025 | globenewswire.comSee More Headlines CMPX Stock Analysis - Frequently Asked Questions How have CMPX shares performed this year? Compass Therapeutics' stock was trading at $1.45 at the beginning of the year. Since then, CMPX stock has increased by 103.4% and is now trading at $2.95. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) released its earnings results on Thursday, May, 8th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). When did Compass Therapeutics IPO? Compass Therapeutics (CMPX) raised $50 million in an initial public offering on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager. Who are Compass Therapeutics' major shareholders? Top institutional shareholders of Compass Therapeutics include Simplicity Wealth LLC (0.06%) and Sequoia Financial Advisors LLC (0.01%). Insiders that own company stock include Orbimed Advisors Llc, Thomas J Schuetz, Vered Bisker-Leib, Jonathan Anderman and Carl L Gordon. View institutional ownership trends. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Alphabet (GOOG). Company Calendar Last Earnings5/08/2025Today8/02/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPX CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Compass Therapeutics$12.67 High Price Target$32.00 Low Price Target$5.00 Potential Upside/Downside+329.4%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.38 million Net MarginsN/A Pretax Margin-6,496.59% Return on Equity-42.47% Return on Assets-38.31% Debt Debt-to-Equity RatioN/A Current Ratio8.33 Quick Ratio8.33 Sales & Book Value Annual Sales$850 thousand Price / Sales479.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book3.24Miscellaneous Outstanding Shares138,283,000Free Float97,075,000Market Cap$407.93 million OptionableNot Optionable Beta1.48 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:CMPX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.